Key result
Qishen Yiqi dropping pills improve Ang II-induced cardiomyocyte hypertrophy and proliferation via the TINCR/miR-193b-3p/RORA axis.
Why the study?
The study was designed to explore the therapeutic effect and mechanism of action of Qishen Yiqi dropping pills in chronic heart failure via a lncRNA-miRNA-mRNA axis.
Does Qishen Yiqi dropping pills (QYDP) improve cardiomyocyte hypertrophy in an Ang II-induced H9C2 model?
Population
Angiotensin II-induced H9C2 cardiomyocyte hypertrophy model
Comparison
Qishen Yiqi dropping pills vs untreated or control conditions
Design
In vitro controlled laboratory study
Authors
Loading...
Supports QYDP mechanistic studies in hypertrophy models; leaves open clinical translation pending in vivo validation.
Does Qishen Yiqi dropping pills (QYDP) improve cardiomyocyte hypertrophy in an Ang II-induced H9C2 model?
Qishen Yiqi dropping pills alleviate Ang II-induced cardiomyocyte hypertrophy in vitro by modulating the TINCR/miR-193b-3p/RORA axis.
Chen et al. (2022) studied chronic heart failure. Qishen Yiqi dropping pills (QYDP) was evaluated on cardiomyocyte hypertrophy and cell proliferation. Qishen Yiqi dropping pills improved Ang II-induced H9C2 cardiomyocyte hypertrophy and increased cell proliferation rate through the TINCR/miR-193b-3p/RORA axis.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: